EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Rapid Decentralized Prostate Cancer Risk Stratification by Portable Liquid Biopsy Analysis within a Clinical Biosensor Validation Framework

Kevin M Koo iD, Grant Phillips, Sriganesh Srihari, Áine Farrell, Binny Jaradi, Kira J Fitzpatrick, John W Yaxley, Hemamali Samaratunga, Paul N Mainwaring, Ke-Lin Ru, Darren J Korbie, Scott A Tomlins und 3 weitere

Advanced Science · 2026

DOI: 10.1002/advs.202512126 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Science, 2026. Verfasst von Kevin M Koo und 14 weiteren Autor:innen. Beteiligte Einrichtung: The University of Queensland Centre for Clinical Research (UQCCR), Brisbane, QLD, Australia. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Biosensing Techniques, Biomarkers, Tumor. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 69 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The University of Queensland Graduate School International Travel Award, National Health and Medical Research Council, Prostate Cancer Foundation of Australia.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Clinical liquid biopsy (e.g., blood or urine) specimens, as a minimally invasive source of crucial molecular information, continue to grow in importance for efficacious targeted cancer treatment. Yet, current molecular profiling technologies are still confined to centralized laboratory testing, which escalates testing costs, result turnaround time, and patient anxiety. Crucially, there is also a scarcity of purposeful clinical validation studies to rigorously evaluate emerging liquid biopsy technologies from research settings to facilitate clinical translation. Here, we report liquid biopsy biosensor advancements in achieving rapid, accurate, and decentralized molecular profiling of a clinically accredited prostate cancer (PCa) urinary circulating RNA biomarker panel. This biosensor approach, termed ‘Accelerated non‐inVasive bioAnalyte testing And Reporting’ (AVATAR), integrates accelerated isothermal assay chemistry and wireless mobile operation capabilities onto a portable electrochemical readout platform. AVATAR enables easy operational control and result display with a custom mobile app following liquid biopsy specimen collection. Using independent training ( n = 124) and validation ( n = 114) PCa clinical urinary specimen cohorts, we showed AVATAR achieved superior PCa risk stratification to current clinical PCa testing with area‐under‐curve values of 0.88 (95% confidence interval: 0.84−0.92) and 0.86 (95% confidence interval: 0.83−0.89), respectively within 55 min of assay time. To further accelerate AVATAR for using PCa liquid biopsies as a surrogate for invasive tissue sampling, we designed a tailored multi‐year PCa follow‐up study with individual patient liquid biopsy specimens showing strong molecular biomarker correlation with comprehensive transcriptomic sequencing of matched tissue specimens ( n = 39). By creating this bespoke biosensor technology clinical translation framework, we demonstrated AVATAR for decentralized PCa liquid biopsy molecular profiling to augment clinical precision cancer management planning.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsBiosensing TechniquesBiomarkers, TumorMaleHumansLiquid BiopsyRisk AssessmentRapid Diagnostic Tests

Stichwörter der Autor:innen

biomarkersbiosensorclinical validationliquid biopsyprostate cancer

Substanzen

Biomarkers, Tumor

Autor:innen und Institutionen

  • The University of Queensland Centre for Clinical Research (UQCCR), Brisbane, QLD, Australia.
  • XING Applied Research & Assay Development (XARAD) Division, XING Technologies Pty Ltd, Brisbane, QLD, Australia.
  • Centre for Personalized Nanomedicine, Australian Institute for Bioengineering and Nanotechnology (AIBN), The University of Queensland, Brisbane, QLD, Australia.
  • QIMR Berghofer Centre for Immunotherapy and Vaccine Development and Translational and Human Immunology Laboratory, Department of Immunology, QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia.
  • Department of Urology, Royal Brisbane and Women's Hospital, Brisbane, QLD, Australia.
  • Aquesta Specialized Uropathology, Brisbane, QLD, Australia.

ORCID-Profile: Kevin M Koo, Matt Trau

Förderung

  • The University of Queensland Graduate School International Travel Award
  • National Health and Medical Research Council
  • Prostate Cancer Foundation of Australia
  • Sylvia and Charles Viertel Charitable Foundation
  • US National Institutes of Health
  • U.S. Department of Defense
  • Prostate Cancer Foundation
  • A. Alfred Taubman Medical Research Institute

Zitieren

APA

Koo, K. M., Phillips, G., Srihari, S., Farrell, Á., Jaradi, B., Fitzpatrick, K. J., Yaxley, J. W., Samaratunga, H., Mainwaring, P. N., Ru, K. L., Korbie, D. J., Tomlins, S. A., Roberts, M. J., Gardiner, R. A., & Trau, M. (2026). Rapid Decentralized Prostate Cancer Risk Stratification by Portable Liquid Biopsy Analysis within a Clinical Biosensor Validation Framework. Advanced Science. https://doi.org/10.1002/advs.202512126

Vancouver

Koo KM, Phillips G, Srihari S, Farrell Á, Jaradi B, Fitzpatrick KJ, et al. Rapid Decentralized Prostate Cancer Risk Stratification by Portable Liquid Biopsy Analysis within a Clinical Biosensor Validation Framework. Advanced Science. 2026. doi:10.1002/advs.202512126

BibTeX
@article{Koo2026,
  author = {Koo, Kevin M and Phillips, Grant and Srihari, Sriganesh and Farrell, Áine and Jaradi, Binny and Fitzpatrick, Kira J and Yaxley, John W and Samaratunga, Hemamali and Mainwaring, Paul N and Ru, Ke-Lin and Korbie, Darren J and Tomlins, Scott A and Roberts, Matthew J and Gardiner, Robert A and Trau, Matt},
  title = {Rapid Decentralized Prostate Cancer Risk Stratification by Portable Liquid Biopsy Analysis within a Clinical Biosensor Validation Framework},
  journal = {Advanced Science},
  year = {2026},
  doi = {10.1002/advs.202512126}
}
Kostenlos starten →